Brief: Arcutis Says New Data Shows Zoryve® (Roflumilast) Cream 0.15% Provided Consistent Improvement Of Atopic Dermatitis In Individuals With Diverse Skin Types
25/09/2024 06:02
Sept 25 (Reuters) - Arcutis Biotherapeutics Inc
ARQT.O :
* NEW DATA SHOWS ZORYVE® (ROFLUMILAST) CREAM 0.15% PROVIDED
CONSISTENT IMPROVEMENT OF ATOPIC DERMATITIS IN INDIVIDUALS WITH
DIVERSE SKIN TYPES
Source text for Eikon: ID:nGNX43G7dp
Further company coverage: ARQT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Canada Przoryve Cream 0.05% Receives Health Canada Approval For Atopic Dermatitis
Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
Arcutis Biotherapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview
Brief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4